At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Market Closed 12-05 16:00:00 EST
187.79
-0.14
-0.07%
盘后187.79
+0.000.00%
16:10 EST
High188.39Low186.07Vol309.44K
Open187.69D1 Closing187.93Amplitude1.23%
Mkt Cap10.82BTradable Cap9.16BTotal Shares57.60M
T/O58.02MT/O Rate0.63%Tradable Shares48.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
GlobeNewswire  ·  12-06 22:30
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
GlobeNewswire  ·  12-05 08:00
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Benzinga_recent_news  ·  12-05 02:53
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Wolfe Research Initiates Coverage on Crane With Outperform Rating, $215 Price Target
MT Newswires Live  ·  12-04 20:14
Wolfe Research Initiates Coverage on Crane With Outperform Rating, $215 Price Target
Why Is ADC Therapeutics Plunging Today
Benzinga_recent_news  ·  12-04 03:40
Why Is ADC Therapeutics Plunging Today
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
GlobeNewswire  ·  12-03
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
GlobeNewswire  ·  12-03
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
prnewswire  ·  11-28
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
prnewswire  ·  11-20
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
Rare Adiantum reniforme var. sinense Wild Population Rediscovered in Three Gorges Reservoir Area
Deep News  ·  11-20
Rare Adiantum reniforme var. sinense Wild Population Rediscovered in Three Gorges Reservoir Area
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
prnewswire  ·  11-20
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Benzinga  ·  11-19
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire  ·  11-19
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill
Benzinga_recent_news  ·  11-15
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
GlobeNewswire  ·  11-13
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Press Release: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Dow Jones  ·  11-10
Press Release: ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Crane (CR): Valuation Perspectives Following Strong Q3 Earnings and Positive Analyst Sentiment
Simply Wall St.  ·  11-09
Crane (CR): Valuation Perspectives Following Strong Q3 Earnings and Positive Analyst Sentiment
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
Dow Jones  ·  11-07
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
GlobeNewswire  ·  11-06
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
GlobeNewswire  ·  11-04
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Introduction

Company Name.
crane
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--